Premium
Chronic Treatment of Rats with SCH‐23390 or Raclopride Does Not Affect the Concentrations of DARPP‐32 or Its mRNA in Dopamine‐Innervated Brain Regions
Author(s) -
Grebb Jack A.,
Girault JeanAntoine,
Ehrlich Michelle,
Greengard Paul
Publication year - 1990
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.1990.tb08839.x
Subject(s) - dopamine , medicine , endocrinology , sch 23390 , raclopride , chemistry , dopamine receptor d1 , striatum , dopamine receptor , nucleus accumbens , neuroscience , biology
Abstract: DARPP‐32 (dopamine‐ and cyclic AMP‐regulated phosphoprotein, M r = 32,000, as determined by sodium dodecyl sulfate‐polyacrylamide gel electrophoresis) is a neuronal phosphoprotein that is enriched in neurons which possess dopamine D 1 receptors, particularly striatonigral neurons. In rat brain slices, the phosphorylation state of DARPP‐32 is regulated by dopamine, acting through the dopamine D 1 receptor and the adenylyl cyclase system. This study reports that chronic blockade (21 days) of either dopamine D 1 receptors by SCH‐23390 or dopamine D 2 receptors by raclopride does not affect the concentrations of DARPP‐32 in specific rat brain regions (striatum, thalamus, hippocampus, frontal cerebral cortical pole). Northern blot analysis indicates that the steady‐state level of DARPP‐32 mRNA in striatum is also unchanged by these treatments.